Fig 1. Peripheral neuropathy induced by platinum-based oxaliplatin.

5% dextrose (Cont), gemcitabine (100 mg/kg; Gem), and oxaliplatin (3 mg/kg; Oxal) were administered by i.p. injection for 30 days as shown in the schedule (a). Body weight was measured at 7-day intervals from the initial treatment (b). Hot plate test for thermal hyperalgesia was performed before the first infusion and again every 14 days. There was no significant difference between control (●) and drug-treated (▲: gemcitabine, □: oxaliplatin) mice (c). Acetone test for cold allodynia was performed before the first infusion and repeated every 15 days. On day 30, paw withdrawal responses to cold stimuli were significantly increased in only the Oxal group (d). Results are representative of two independent experiments. Values are expressed as the mean ± SEM (n = 12 per group). *p < 0.05, ***p < 0.001 compared with the control group. BT: behavioral test, BW: body weight